Pertuzumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: HER2-Positive Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Treatment of unresectable or recurrent HER2- positive breast cancer
Product first approved 2013PMDA
EU
  • Metastatic Breast Cancer: Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. Neoadjuvant Treatment of Breast Cancer: Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.
Product first approved 2013EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (56)
Breast Cancer
NCT06876714 · Alliance for Clinical Trials in Oncology
2025-09-17 – 2037-03-13 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
What this study did
NCT06057610 · Jiangsu HengRui Medicine Co., Ltd.
2023-11-01 – 2032-10 · HER2-PositiveRecurrent or Metastatic Breast Cancer
What this study did
NCT05883852 · Fudan University
2023-06-07 – 2031-07-01 · HER2 Positive Early Breast Cancer
What this study did
NCT07683754 · Daiichi Sankyo
2026-11-04 – 2030-08-28 · Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
What this study did
NCT07797218 · Shanghai Jiao Tong University School of Medicine
2026-07-01 – 2030-06-30 · Breast Cancer Early Stage Breast Cancer (Stage 1-3)
What this study did
NCT04784715 · AstraZeneca
2021-04-26 – 2029-12-31 · Breast Cancer; HER2-positive; Metastatic
What this study did
NCT07057427 · Henan Cancer Hospital
2025-06-24 – 2029-06-30 · Breast Cancer
What this study did
NCT04973319 · Shengjing Hospital
2021-08-01 – 2027-08-01 · Breast Cancer
What this study did
NCT04193059 · Fudan University
2019-12-20 – 2027-07 · Breast Cancer
What this study did
NCT05113251 · AstraZeneca
2021-10-25 – 2027-04-30 · Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
What this study did
NCT03595592 · Fondazione Michelangelo
2018-09-07 – 2027-03-15 · Invasive Breast Cancer
What this study did
NCT04514419 · BioRay Pharmaceutical Co., Ltd.
2020-06-28 – 2025-12 · Breast Cancer
What this study did
NCT02003209 · National Cancer Institute (NCI)
2014-02-18 – 2025-06-30 · HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
What this study did
NCT02344472 · Prof. Wolfgang Janni
2015-09 – 2025-01-31 · Metastatic Breast Cancer
What this study did
NCT03264547 · Japan Breast Cancer Research Group
2017-08-28 – 2024-12-31 · Breast Cancer
What this study did
NCT05429684 · First Affiliated Hospital Xi'an Jiaotong University
2021-01-01 – 2024-02-28 · HER2+ Breast Cancer
What this study did
NCT05283837 · Zydus Lifesciences Limited
2022-09-26 – 2023-09-06 · Metastatic Breast Cancer
What this study did
NCT02514681 · Japan Breast Cancer Research Group
2015-08-01 – 2022-08-10 · HER2-positive Locally Advanced or Metastatic Breast Cancer
What this study did
NCT02402712 · Hoffmann-La Roche
2015-05-06 – 2019-02-22 · Breast Cancer
What this study did
NCT01026142 · Hoffmann-La Roche
2010-01-26 – 2017-08-07 · Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT07578116 · SWOG Cancer Research Network
2027-03-09 – 2033-05-31 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
What this study did
NCT07748260 · Guangdong Provincial People's Hospital
2026-09-01 – 2031-07-01 · HER2-positive Breast Cancer
What this study did
NCT02947685 · Alliance Foundation Trials, LLC.
2017-06-21 – 2030-12-31 · HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
What this study did
NCT01996267 · The Netherlands Cancer Institute
2013-12-21 – 2030-12-15 · Breast Cancer, HER2 Positive
What this study did
NCT07377643 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
2026-02-10 – 2030-05-31 · HER2-positive Breast Cancer
What this study did
NCT07518173 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-04-21 – 2029-12 · HER2-positive Breast Cancer
What this study did
NCT04337658 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-07-01 – 2026-04-30 · HER2-positive Breast Cancer
What this study did
NCT05720026 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2023-01-09 – 2026-02-21 · HER2-positive Breast Cancer
What this study did
NCT05802225 · Biocad
2023-01-30 – 2026-02-20 · Breast Cancer
What this study did
NCT05415215 · Hoffmann-La Roche
2022-07-05 – 2025-11-07 · Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer
What this study did
NCT02625441 · Helsinki University Central Hospital
2015-12 – 2025-06-01 · Breast Cancer
What this study did
NCT04858529 · Guangdong Provincial People's Hospital
2021-04-30 – 2025-04-30 · Neoadjuvant Therapies for HER2+ Breast Cancer
What this study did
NCT05474690 · Henan Cancer Hospital
2022-05-11 – 2024-08-30 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT05985187 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-10-20 – 2023-12 · HER2-positive Breast Cancer
What this study did
NCT04957212 · Cinnagen
2018-08-11 – 2020-05-27 · HER2-positive Breast Cancer
What this study did
NCT03811418 · iOMEDICO AG
2019-01 – 2019-04 · Advanced Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT02125344 · GBG Forschungs GmbH
2014-12 – 2017-01-30 · Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer
What this study did
Phase 2/3 (6)
Breast Cancer
NCT07294508 · Shanghai Henlius Biotech
2026-02-27 – 2030-12-30 · HER2 + Breast Cancer
What this study did
NCT07294534 · Shanghai Henlius Biotech
2026-01-27 – 2030-02-01 · HER2 + Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT06891833 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-06-05 – 2028-12 · HER2-positive Breast Cancer
What this study did
Other / comorbidity
NCT05722886 · Cancer Research UK
2023-03-01 – 2029-10 · Haematological Malignancy, Solid Tumour
What this study did
NCT05786716 · Cancer Research UK
2023-03-07 – 2029-10 · Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm, Solid Tumour
What this study did
NCT02581462 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2016-06 – 2020-07-17 · Stomach Cancer, Gastroesophageal Junction Cancer
What this study did
Phase 2 (153)
Breast Cancer
NCT04266249 · ECOG-ACRIN Cancer Research Group
2020-03-13 – 2038-12-31 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
What this study did
NCT07616427 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-05-20 – 2033-05-20 · HR+/HER2+ Early Breast Cancer
What this study did
NCT07246317 · Tianjin Medical University Cancer Institute and Hospital
2025-12-15 – 2032-12-31 · Breast Cancer
What this study did
NCT07772245 · Polly A. Niravath, MD
2026-12-31 – 2032-12-31 · HER2-addicted Breast Cancer
What this study did
NCT07393425 · Shanghai Jiao Tong University School of Medicine
2026-02-02 – 2032-09-30 · HER2 + Breast Cancer
What this study did
NCT07679269 · Novartis Pharmaceuticals
2026-12-15 – 2032-04-20 · PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
What this study did
NCT06510465 · RenJi Hospital
2024-08-01 – 2032-03-31 · Breast Cancer
What this study did
NCT07220135 · University of Kansas Medical Center
2025-11-14 – 2031-05-14 · Breast Cancer
What this study did
NCT07047755 · Henan Cancer Hospital
2025-07-01 – 2031-02-28 · Breast Cancer
What this study did
NCT07340398 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-12-25 – 2031-01-01 · HER2-positive Early Breast Cancer
What this study did
NCT06927180 · Henan Cancer Hospital
2025-04-16 – 2030-12-01 · Breast Cancer Early Stage Breast Cancer (Stage 1-3)
What this study did
NCT05332561 · German Cancer Research Center
2023-06-29 – 2030-12 · Early-stage Breast Cancer
What this study did
NCT07371585 · SOLTI Breast Cancer Research Group
2026-02-18 – 2030-07-01 · Breast Cancer Stage IV
What this study did
NCT02624973 · Haukeland University Hospital
2016-04-15 – 2030-06 · Breast Cancer
What this study did
NCT07610720 · Sun Yat-sen University
2026-06-01 – 2029-11-01 · Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer
What this study did
NCT03820141 · The Methodist Hospital Research Institute
2020-06-30 – 2028-12 · Breast Cancer
What this study did
NCT07857226 · Hebei Medical University Fourth Hospital
2026-09 – 2028-12 · Breast Cancer
What this study did
NCT07407920 · M.D. Anderson Cancer Center
2025-10-09 – 2028-09-30 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma, Early Stage Triple-Negative Breast Carcinoma
What this study did
NCT07402473 · Rutgers, The State University of New Jersey
2026-03-26 – 2028-06-30 · HER2-positive Early-stage Breast Cancer
What this study did
NCT04733118 · MedSIR
2021-08-05 – 2028-03 · Early Breast Cancer
What this study did
NCT04329065 · University of Washington
2022-04-20 – 2027-12-31 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
What this study did
NCT05978648 · wang shusen
2023-09-20 – 2027-12-31 · Breast Neoplasms
What this study did
NCT07299890 · Anhui Provincial Cancer Hospital
2025-12-20 – 2027-11-01 · Breast Cancer
What this study did
NCT05323955 · Carey Anders, M.D.
2023-03-23 – 2027-11 · Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
What this study did
NCT05983094 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-09-01 – 2027-09-01 · Breast Cancer, Neoadjuvant Therapy
What this study did
NCT02827877 · City of Hope Medical Center
2018-02-14 – 2027-08-26 · HER2 Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
What this study did
NCT07335081 · Shanghai Jiao Tong University School of Medicine
2024-02-01 – 2026-12-31 · Breast Cancer
What this study did
NCT04172259 · Sun Yat-sen University
2019-01-10 – 2026-09-30 · Breast Cancer, Neoadjuvant Chemotherapy
What this study did
NCT04680442 · Population Health Research Institute
2021-07-01 – 2026-06-30 · Breast Cancer, Heart Failure
What this study did
NCT05041842 · UNICANCER
2021-12-17 – 2026-04-30 · Metastatic Breast Cancer With a Isolated Brain Progression
What this study did
NCT03417544 · Nancy Lin, MD
2018-05-21 – 2026-04-17 · HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
What this study did
NCT01796197 · Dana-Farber Cancer Institute
2013-08 – 2026-01 · Breast Cancer
What this study did
NCT05353361 · Jiangsu HengRui Medicine Co., Ltd.
2022-05-23 – 2025-12-31 · Breast Cancer
What this study did
NCT04591431 · Fondazione per la Medicina Personalizzata
2020-10-07 – 2025-06 · Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
What this study did
NCT04197687 · Academic and Community Cancer Research United
2020-02-20 – 2025-01-15 · Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
What this study did
NCT05180006 · Gustave Roussy, Cancer Campus, Grand Paris
2022-02-24 – 2024-12-17 · Breast Cancer
What this study did
NCT05749016 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2021-11-01 – 2023-12-01 · Locally Advanced Breast Cancer, Chemotherapy Effect
What this study did
NCT03412643 · NSABP Foundation Inc
2018-05-14 – 2023-10-30 · HER2-negative Breast Cancer
What this study did
NCT05483439 · Shengjing Hospital
2021-10-20 – 2023-07-01 · Stage II-III Breast Cancer
What this study did
NCT03742986 · NYU Langone Health
2019-05-02 – 2023-06-12 · Breast Cancer
What this study did
NCT01597414 · European Organisation for Research and Treatment of Cancer - EORTC
2013-06 – 2022-11 · Elderly Metastatic Breast Cancer Population
What this study did
NCT02229149 · US Oncology Research
2014-12 – 2022-01 · Breast Neoplasms, Malignant Tumor of the Breast
What this study did
NCT03144947 · Gruppo Oncologico Italiano di Ricerca Clinica
2016-11-29 – 2021-11 · Cancer, Breast
What this study did
NCT03329378 · Icahn School of Medicine at Mount Sinai
2019-01-24 – 2021-03-07 · Locally Advanced Breast Cancer
What this study did
Phase 1/2 (23)
Breast Cancer
NCT04538742 · AstraZeneca
2020-12-28 – 2030-01-31 · Metastatic Breast Cancer
What this study did
NCT03101748 · M.D. Anderson Cancer Center
2018-02-19 – 2025-05-13 · Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT05574881 · Fudan University
2022-09-01 – 2025-01-01 · Breast Cancer
What this study did
NCT02139358 · H. Lee Moffitt Cancer Center and Research Institute
2014-09-05 – 2020-03-16 · Breast Cancer
What this study did
NCT02336984 · H. Lee Moffitt Cancer Center and Research Institute
2014-06 – 2016-04-04 · Breast Cancer
What this study did
NCT00934856 · Hoffmann-La Roche
2009-07 – 2013-10 · Breast Cancer
What this study did
NCT00951665 · Genentech, Inc.
2009-08 – 2013-06 · Metastatic Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT06686394 · Merck Sharp & Dohme LLC
2025-02-26 – 2032-08-02 · Breast Neoplasms, Breast Cancer
What this study did
NCT07612215 · NYU Langone Health
2026-05-13 – 2030-05 · ER Positive, HER2 Positive Breast Cancer
What this study did
NCT07739511 · Liu Shu
2026-07-29 – 2029-07-30 · HER2 + Breast Cancer
What this study did
NCT05593094 · Hoffmann-La Roche
2020-09-03 – 2027-08-31 · Advanced Solid Tumors, HER2-positive Breast Cancer
What this study did
NCT04588545 · H. Lee Moffitt Cancer Center and Research Institute
2020-12-10 – 2027-05 · HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
What this study did
NCT03112590 · H. Lee Moffitt Cancer Center and Research Institute
2017-06-23 – 2023-02-20 · Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
What this study did
NCT04108858 · National Cancer Institute (NCI)
2021-05-20 – 2022-04-29 · Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
What this study did
NCT02345772 · Western Regional Medical Center
2014-07 – 2015-11 · HER2-positive Breast Cancer, ER-positive Breast Cancer
What this study did
NCT02379585 · Western Regional Medical Center
2013-01 – 2015-08 · HER2-positive Breast Cancer
What this study did
Other / comorbidity
NCT06771622 · FBD Biologics Limited
2025-03-13 – 2029-01-01 · Solid Cancer
What this study did
NCT07140393 · Jiangsu HengRui Medicine Co., Ltd.
2025-10-28 – 2028-10 · Solid Tumor
What this study did
NCT03304080 · Icahn School of Medicine at Mount Sinai
2017-12-20 – 2027-12-31 · Breast Neoplasms, Breast Diseases
What this study did
NCT05150691 · DualityBio Inc.
2022-01-31 – 2027-10 · HER2-positive Advanced Solid Tumor
What this study did
NCT02120911 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2014-01 – 2017-02 · Esophageal Carcinoma
What this study did
NCT00551421 · National Cancer Institute (NCI)
2007-10 – 2012-06 · Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
What this study did
Phase 1 (29)
Breast Cancer
NCT03716180 · Dana-Farber Cancer Institute
2018-11-05 – 2030-09-01 · Breast Cancer
What this study did
NCT04188548 · Eli Lilly and Company
2019-12-10 – 2027-12 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
What this study did
NCT04692831 · Memorial Sloan Kettering Cancer Center
2020-11-30 – 2027-11-30 · HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression, HER2-positive Metastatic Breast Cancer
What this study did
NCT02057133 · Eli Lilly and Company
2014-03-10 – 2026-12 · Breast Neoplasms
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT04253561 · SOLTI Breast Cancer Research Group
2020-02-25 – 2025-06-17 · Metastatic Breast Cancer
What this study did
NCT02390427 · Nancy Lin, MD
2015-04-20 – 2024-07 · Metastatic Breast Cancer, Recurrent Breast Cancer
What this study did
NCT05471648 · EirGenix, Inc.
2022-05-16 – 2023-01-24 · Breast Cancer
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT02605915 · Hoffmann-La Roche
2015-12-31 – 2019-11-13 · HER2-Positive Metastatic Breast Cancer, HER2-Negative Metastatic Breast Cancer, Locally Advanced or Early Breast Cancer
What this study did
NCT02738970 · Hoffmann-La Roche
2016-06-23 – 2018-05-31 · Early Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT06162559 · The Netherlands Cancer Institute
2023-12-18 – 2036-05 · Breast Cancer
What this study did
NCT05385705 · Vall d'Hebron Institute of Oncology
2022-05-11 – 2024-07-11 · Breast Neoplasms
What this study did
NCT03135171 · University of Michigan Rogel Cancer Center
2017-07-26 – 2020-03-20 · Breast Cancer
What this study did
NCT02060253 · Memorial Sloan Kettering Cancer Center
2014-04 – 2018-06 · HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
What this study did
NCT02598427 · Kimberly Blackwell
2017-05-01 – 2018-02-22 · HER2 Positive Untreated Metastatic Breast Cancer, Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
What this study did
NCT01875666 · UNC Lineberger Comprehensive Cancer Center
2013-08-05 – 2016-12-19 · Breast Neoplasms
What this study did
Other / comorbidity
NCT05825781 · Mabscale, LLC
2023-07-20 – 2024-09 · Healthy Men
What this study did
NCT03109977 · Memorial Sloan Kettering Cancer Center
2017-03-31 – 2018-04-12 · HER2-positive Carcinoma, HER2-positive Primary Malignancy
What this study did
NCT02593708 · Michelle Melisko
2015-11-03 – 2017-07-31 · Solid Tumor
What this study did
NCT02507375 · Hoffmann-La Roche
2006-09 – 2008-12 · Non-Small Cell Lung Cancer
What this study did
NCT02490475 · Hoffmann-La Roche
2004-02 – 2006-04 · Solid Tumor
What this study did
NCT00027027 · Genentech, Inc.
2001-11 – 2003-08 · Neoplasms
What this study did
Phase 4 (8)
Breast Cancer
NCT07695259 · Wen-Ming Cao
2026-05-25 – 2027-12-31 · Elderly Females, HER2 + Breast Cancer, Neoadjuvant Therapy
What this study did
NCT05420454 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-07-10 – 2027-12-20 · Breast Cancer
What this study did
NCT05420467 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-07-10 – 2027-12-20 · Breast Cancer
What this study did
NCT06578299 · Fudan University
2024-08-30 – 2027-08-30 · Breast Cancer Stage IV
What this study did
NCT02445586 · Hoffmann-La Roche
2015-08-17 – 2018-09-26 · Breast Cancer
What this study did
NCT01501487 · Agendia
2011-10 – 2017-06 · Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT07093931 · Shandong Cancer Hospital and Institute
2025-08-01 – 2030-08-01 · Breast Cancer
What this study did
NCT05036005 · Institut fuer Frauengesundheit
2021-07-11 – 2023-07 · Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer
What this study did
Early phase / not applicable (7)
Breast Cancer
NCT01048099 · SCRI Development Innovations, LLC
2011-01 – 2014-07 · Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT07589972 · Tianjin Medical University Cancer Institute and Hospital
2026-04-20 – 2028-12-31 · Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
What this study did
NCT07187752 · Shandong Cancer Hospital and Institute
2025-09-30 – 2027-06-30 · Breast Cancer
What this study did
NCT06907082 · Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
2020-12-28 – 2024-03-14 · Breast Cancer
What this study did
NCT07115095 · Nanlin Li
2021-01-01 – 2023-01-01 · HER2-positive Breast Cancer
What this study did
Used as active comparator (32)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (13)
Breast Cancer
NCT06278870 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-09-06 – 2031-06-30 · HER2-positive Metastatic Breast Cancer, First-line Treatment
What this study did
NCT07003074 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
2025-06-23 – 2030-07 · Breast Cancer
What this study did
NCT05838066 · Shanghai JMT-Bio Inc.
2023-07-23 – 2027-12-31 · First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT07441460 · Shanghai JMT-Bio Inc.
2026-03-06 – 2035-08-07 · Resectable HER2-positive Breast Cancer
What this study did
NCT07043725 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
2025-09-15 – 2029-09 · HER2-positive Breast Cancer
What this study did
NCT07196774 · Jiangsu HengRui Medicine Co., Ltd.
2025-10-23 – 2028-12 · Early-stage or Locally Advanced HER2-positive Breast Cancer
What this study did
NCT05760612 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-03-14 – 2028-11-01 · Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab, RCB Classification 1-2, Neratini
What this study did
NCT06747338 · Shanghai JMT-Bio Inc.
2024-12-16 – 2027-12-16 · Early or Locally Advanced HER2-positive Breast Cancer
What this study did
NCT07386938 · R-Pharm
2024-08-09 – 2027-05-28 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT05346224 · Shanghai Henlius Biotech
2022-04-25 – 2025-12-30 · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
What this study did
Phase 2/3 (2)
HER2-Positive Breast Cancer
NCT02568839 · Thomas Hatschek
2014-11 – 2029-02 · Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer
What this study did
Phase 2 (12)
Breast Cancer
NCT07136974 · Henan Cancer Hospital
2025-09-01 – 2030-08-30 · Breast Cancer, HER2 + Breast Cancer
What this study did
NCT05292742 · Fujian Medical University Union Hospital
2021-07-02 – 2027-12-31 · Breast Cancer, Adjuvant Therapy
What this study did
NCT07545044 · Shanghai JMT-Bio Inc.
2026-05-30 – 2027-05-30 · HER2-positive Recurrent or Metastatic Breast Cancer
What this study did
NCT04900311 · Tianjin Medical University Cancer Institute and Hospital
2021-05 – 2025-12 · HER2+ Early or Locally Advanced Breast Cancer
What this study did
NCT04246502 · Shandong Cancer Hospital and Institute
2020-01 – 2024-12 · Metastatic Breast Cancer
What this study did
NCT04717531 · The First Affiliated Hospital with Nanjing Medical University
2021-06-03 – 2024-05-31 · Breast Cancer
What this study did
NCT02073487 · The Methodist Hospital Research Institute
2014-02 – 2019-01 · Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT07856303 · Fudan University
2026-10-01 – 2034-08 · HER2-positive Breast Cancer, Early Breast Cancer (EBC)
What this study did
NCT05900206 · Karolinska University Hospital
2023-10-26 – 2032-04-30 · Breast Cancer
What this study did
NCT07053085 · Memorial Sloan Kettering Cancer Center
2025-09-17 – 2029-09-17 · Metastatic Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT04760431 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-10-01 – 2025-09-30 · HER2-positive Breast Cancer, Brain Metastases
What this study did
Phase 1/2 (1)
HER2-Positive Breast Cancer
NCT05319873 · Jonsson Comprehensive Cancer Center
2022-04-07 – 2028-04-01 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Positive Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
Phase 1 (4)
Breast Cancer
NCT07861139 · Qilu Pharmaceutical Co., Ltd.
2026-10 – 2027-09 · Breast Cancer
What this study did
Other / comorbidity
NCT05323981 · BioRay Pharmaceutical Co., Ltd.
2022-04-11 – 2022-10-09 · Similarity of Pharmacokinetics and Safety
What this study did
NCT04411550 · Shanghai Henlius Biotech
2020-07-01 – 2021-07-30 · Healthy Male Volunteers
What this study did
NCT04820439 · The Affiliated Hospital of Qingdao University
2020-10-13 – 2021-03-13 · Healthy Volunteers
What this study did
Studied as part of a combination product (2)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (1)
Other / comorbidity
NCT05256225 · National Cancer Institute (NCI)
2022-11-16 – 2027-10-31 · Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
What this study did
Early phase / not applicable (1)
HER2-Positive Breast Cancer
NCT07095023 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-08-15 – 2029-06-30 · Breast Cancers
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (4)
Breast Cancer
NCT04208178 · Novartis Pharmaceuticals
2020-07-16 – 2027-02-26 · Advanced HER2+Breast Cancer
What this study did
NCT03199885 · National Cancer Institute (NCI)
2019-04-05 – 2025-04-04 · Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma, Recurrent HER2-Positive Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Unresectable Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma
What this study did
HER2-Positive Breast Cancer
NCT05132582 · Seagen, a wholly owned subsidiary of Pfizer
2022-03-07 – 2027-09-28 · HER2 Positive Breast Cancer
What this study did
Phase 2 (1)
HER2-Positive Breast Cancer
NCT07848633 · The First Affiliated Hospital with Nanjing Medical University
2026-10-01 – 2029-12-31 · HER 2 Positive Advanced Breast Cancer
What this study did
Phase 1/2 (2)
Breast Cancer
NCT06555068 · Jiangsu HengRui Medicine Co., Ltd.
2024-08-12 – 2028-08 · Advanced Unresectable or Metastatic Breast Cancer, Advanced Solid Tumors
What this study did
HER2-Positive Breast Cancer
NCT01922921 · University of Washington
2014-02-05 – 2021-09-01 · HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer
What this study did
Early phase / not applicable (1)
Breast Cancer
NCT06190600 · The Greater Poland Cancer Centre
2018-10-11 – 2026-12-31 · Breast Cancer
What this study did

Competitive landscape

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pertuzumab: this drugApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(93 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pertuzumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (12)
November 2026 (1)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-11 · NCT05323955 · CT.gov ↗
What to watch
December 2026 (11)
Phase 2HER2-Positive Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT03125928 · CT.gov ↗
What to watch
Phase 3Metastatic Colon Cancer, Stage III Colon CancerActive not recruiting
Est. primary completion 2026-12 · NCT03803553 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2026-12 · NCT05891561 · CT.gov ↗
What to watch
Phase 2Rectal Cancer, HER2-positiveRecruiting
Est. primary completion 2026-12-01 · NCT07108127 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2026-12-15 · NCT03595592 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2026-12-15 · NCT07245797 · CT.gov ↗
What to watch
Phase 1Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT03006172 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT04329065 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT05978648 · CT.gov ↗
What to watch
Early phase / not applicableHER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT07187752 · CT.gov ↗
What to watch
2027 (36)
February 2027 (1)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-02 · NCT05325632 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-03 · NCT04733118 · CT.gov ↗
What to watch
Phase 3Solid TumorsActive not recruiting
Est. primary completion 2027-03-28 · NCT02320435 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-03-31 · NCT06510465 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1/2HER2-Positive Breast CancerActive not recruiting
Est. primary completion 2027-04 · NCT04588545 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-05-03 · NCT04784715 · CT.gov ↗
What to watch
June 2027 (2)
Phase 4Breast CancerRecruiting
Est. primary completion 2027-06-10 · NCT05420454 · CT.gov ↗
What to watch
Phase 2Neoplasm MetastasisActive not recruiting
Est. primary completion 2027-06-30 · NCT00781612 · CT.gov ↗
What to watch
July 2027 (6)
Phase 3Esophageal Cancer, Esophageal AdenocarcinomaRecruiting
Est. primary completion 2027-07 · NCT05188313 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-07 · NCT07528898 · CT.gov ↗
What to watch
Phase 4Breast CancerRecruiting
Est. primary completion 2027-07-10 · NCT05420467 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-07-15 · NCT04301375 · CT.gov ↗
What to watch
Phase 1/2Breast Neoplasms, Breast DiseasesActive not recruiting
Est. primary completion 2027-07-31 · NCT03304080 · CT.gov ↗
What to watch
Phase 1/2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-07-31 · NCT07739511 · CT.gov ↗
What to watch
August 2027 (6)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-08 · NCT05020860 · CT.gov ↗
What to watch
Phase 1/2HER2-positive Advanced Solid TumorRecruiting
Est. primary completion 2027-08 · NCT05150691 · CT.gov ↗
What to watch
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2027-08-01 · NCT04973319 · CT.gov ↗
What to watch
Phase 4HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-08-01 · NCT07093931 · CT.gov ↗
What to watch
Phase 1/2HER2-Positive Breast CancerActive not recruiting
Est. primary completion 2027-08-31 · NCT05593094 · CT.gov ↗
What to watch
Phase 2Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-08-31 · NCT07716111 · CT.gov ↗
What to watch
September 2027 (2)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-09-30 · NCT07393425 · CT.gov ↗
What to watch
October 2027 (2)
Phase 1/2Solid TumorRecruiting
Est. primary completion 2027-10 · NCT07140393 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-10-31 · NCT04266249 · CT.gov ↗
What to watch
November 2027 (4)
Phase 2Biliary Tract Cancer (BTC), First-line TherapyNot yet recruiting
Est. primary completion 2027-11 · NCT07129018 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-11-01 · NCT07299890 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-11-14 · NCT07220135 · CT.gov ↗
What to watch
Phase 1Breast CancerActive not recruiting
Est. primary completion 2027-11-30 · NCT04692831 · CT.gov ↗
What to watch
December 2027 (8)
Phase 4Breast CancerRecruiting
Est. primary completion 2027-12-01 · NCT07695259 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-12-29 · NCT07102381 · CT.gov ↗
What to watch
Phase 2Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07246317 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07402473 · CT.gov ↗
What to watch
Early phase / not applicableHER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07589972 · CT.gov ↗
What to watch
2028 (18)
January 2028 (2)
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 2/3Breast CancerRecruiting
Est. primary completion 2028-01-15 · NCT07294508 · CT.gov ↗
What to watch
March 2028 (3)
Phase 2Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis), Gastroesophageal Junction Cancer, Biliary Tract Cancer (BTC)Not yet recruiting
Est. primary completion 2028-03-01 · NCT07938021 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2028-03-13 · NCT06876714 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-03-30 · NCT07795424 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-04-28 · NCT07377643 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-05-20 · NCT07616427 · CT.gov ↗
What to watch
June 2028 (5)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-06 · NCT06441890 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07857226 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2028-06-15 · NCT05296798 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2028-06-30 · NCT07057427 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2028-06-30 · NCT07797218 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2/3Breast CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07294534 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-09-30 · NCT07407920 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-11-01 · NCT07610720 · CT.gov ↗
What to watch
December 2028 (2)
Phase 2/3HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-12 · NCT06891833 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT07340398 · CT.gov ↗
What to watch
2029 (13)
February 2029 (1)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2029-02-28 · NCT07581795 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2HER2-Positive Breast CancerActive not recruiting
Est. primary completion 2029-03-23 · NCT04569747 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Cancer, Tumors, Neoplasms, NeoplasiaRecruiting
Est. primary completion 2029-04-30 · NCT04341181 · CT.gov ↗
What to watch
May 2029 (3)
Phase 1/2HER2-Positive Breast CancerRecruiting
Est. primary completion 2029-05 · NCT07612215 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2029-05-01 · NCT06927180 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2029-05-01 · NCT07527806 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2029-06 · NCT07647263 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2029-08-01 · NCT07371585 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2/3Haematological Malignancy, Solid TumourRecruiting
Est. primary completion 2029-10 · NCT05722886 · CT.gov ↗
What to watch
Phase 2/3Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm …Recruiting
Est. primary completion 2029-10 · NCT05786716 · CT.gov ↗
What to watch
December 2029 (3)
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2029-12 · NCT07518173 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07565324 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07772245 · CT.gov ↗
What to watch
2030 (7)
March 2030 (4)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-03 · NCT05332561 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-03-04 · NCT07459673 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-03-30 · NCT06439693 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma of the Head and NeckEnrolling by invitation
Est. primary completion 2030-03-31 · NCT07550972 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2030-07-04 · NCT07683754 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2030-08-31 · NCT07716046 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2031 (3)
July 2031 (2)
Phase 3Breast CancerRecruiting
Est. primary completion 2031-07-01 · NCT05883852 · CT.gov ↗
What to watch
Phase 3HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2031-07-01 · NCT07748260 · CT.gov ↗
What to watch
November 2031 (1)
Phase 2Advanced Cancer, Solid Tumor, Haematological MalignancyRecruiting
Est. primary completion 2031-11-25 · NCT05159245 · CT.gov ↗
What to watch
2032 (3)
March 2032 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2032-03-23 · NCT07679269 · CT.gov ↗
What to watch
May 2032 (1)
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2032-05-31 · NCT07578116 · CT.gov ↗
What to watch
August 2032 (1)
Phase 1/2HER2-Positive Breast CancerRecruiting
Est. primary completion 2032-08-02 · NCT06686394 · CT.gov ↗
What to watch
2034 (1)
July 2034 (1)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2034-07-01 · NCT06348134 · CT.gov ↗
What to watch

See the full readout calendar ↗